FDA accepts second application for Ocular Therapeutix ’ s drug-delivering implant

Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has accepted a new supplemental New Drug Application for its Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery. The Bedford, Mass.-based company’s device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops. Read the whole story on our sister site, Drug Delivery Business News
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance oculartherapeutix Source Type: news